Please login to the form below
Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more
It's not just the GDPR's big day, plus news from Medigene and Pfizer
Digital skills gap hinders UK healthcare innovation
Report calls for greater emphasis on HCPs’ digital and data literacy education
FDA starts review of Sanofi’s oral type 1 diabetes drug
FDA clears Dova drug for liver-related low blood platelets
Drug is in the same class as Novartis’ Promacta/Revolade
AZ gets US approval for Veltassa rival Lokelma
But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia
Novartis, Amgen set low price for first CGRP migraine drug
Aimovig has a list price of $6,900 per year
Pharma and biotech leaders back ’no deal’ Brexit warning
Ongoing division in Conservative party means 'no deal' remains a possibility
Breakthrough Device status for novel blood filtering immunotherapy
Novel technology aims to reactivate immune system in cancer patients
Despite FDA concerns, Akcea rare disease drug clears FDA panel
FDA now set to deliver final verdict by 30 August
Moving times
Continuity and stability are vital when it comes to the EMA's relocation when it leaves London
-
SMC gives green light for Amgen’s KyprolisThe committee also gives verdict on three other products
-
Facing the new wave of biosimilarsDon’t drown out the patient voice, says advocacy group
-
Daily BriefA rapid round-up of the top pharma, biotech and healthcare news
-
Maintenance OK boosts AstraZeneca’s Lynparza in EuropeNew pill formulation also helps AZ and MSD against competitors in PARP class
-
NHS England pledges to streamline clinical trial setupThe process will also target the procedure for reimbursements in additional treatment costs
-
Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrandsA rapid round-up of the top pharma, biotech and healthcare news
-
FDA clears first-line use for J&J's DarzalexFront-line approval a milestone for blockbuster-tipped myeloma drug
-
Roche eyes September FDA verdict for triple NSCLC therapyRoche hot on the heels of Merck in first-line non-small cell lung cancer market
-
Morning brief: New biotech launched, Merck and Moderna expand collaboration and moreA rapid round up of pharma, biotech and healthcare news
Latest regulatory appointments
-
Professor Carole Longson moves from NICE to the ABPIShe joins the UK pharma body as its chief scientific officer
-
MedTech Europe appoints new board of directors
Chair of the board Michelle Brennan is among those newly elected
-
Greg Perry joins IFPMA as assistant director generalWill move to the global industry body from the Medicines Patent Pool
-
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
He joins the biopharma from Tang Capital Management
-
IFPMA names new communications director
Helen Gallagher joins the association from Ferring Pharmaceuticals
Featured jobs
-
Associate Director, Healthcare PR
-
£60, 000 – £67, 000+ benefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Scientific Engagement Director
-
Salary will be dependant on experience
- Medical Writer - Medical Communications
-
£30, 000 - £40, 000 according to skills and experience plus benefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Scientific Director
-
Great salary and bebefits
-
Product Manager - Hertfordshire
-
Competitive salary depending on experience benefits
- Senior Account Director or Business Unit Director, Healthcare Ad...
-
C£60, 000 – £70, 000 benefits
-
Senior Medical Writer
-
Great salary and bebefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Assistant Product Manager - Hertfordshire
-
Competitive salary depending on experience benefits
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Sales & Marketing Manager - New Launch - Mental Health - S E...
-
Highly Competitive Basic, Bonus &Benefits
Subscribe to our email news alerts
- Foundry3 set sights on tailored patient support programmes
- FDA starts review of Sanofi’s oral type 1 diabetes drug
- Moving annual total (MAT)
- Key success factor (KSF)
- Bluebird bags breakthrough status for CALD gene therapy
- Daily Brief: AstraZeneca's new San Fran home, Keytruda triumphs again, Novo branches out
- Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more
- Synergy Vision shortlisted as finalists for two awards at the 2018 Communiqué Awards
- AstraZeneca expands alliance with Bicycle Therapeutics
- AbbVie trial backs chemo-free Imbruvica combo regimen
- The call for a more strategic medical affairs community
- Transparency and accountability: tackling opacity and blame head-on
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Beyond the event
- ...
- Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
- Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
- Is the pharma business model ready for precision medicine?
- Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
Quick links
Infographics
